HIA
JAZZ icon

HFM Investment Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

HFM Investment Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41K Buy
10
+5
+100% +$1.09K ﹤0.01% 386
2026
Q1 		$945 Hold
5
– – ﹤0.01% 426
2025
Q4 		$850 Hold
5
– – ﹤0.01% 513
2025
Q3 		$659 Hold
5
– – ﹤0.01% 545
2025
Q2 		$531 Buy
5
+3
+150% +$326 ﹤0.01% 631
2025
Q1 		$249 Buy
+2
New +$261 ﹤0.01% 546

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

HFM Investment Advisors's JAZZ Position: Q2 2026 in Review

HFM Investment Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 100% in Q2 2026, buying an estimated $1.09K and bringing the position to 10 shares worth $2.41K. The position accounts for ﹤0.01% of the portfolio, ranked #386.

HFM Investment Advisors first reported a position in JAZZ in Q1 2025 and has held it in 6 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • HFM Investment Advisors held 10 shares of Jazz Pharmaceuticals worth $2.41K as of Q2 2026.
  • HFM Investment Advisors bought 5 Jazz Pharmaceuticals shares in Q2 2026, an estimated $1.09K.
  • Jazz Pharmaceuticals made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #386 holding.
  • HFM Investment Advisors first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.